Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot, Theodora Bejan-Angoulvant, Céline Desvignes, Denis Mulleman, Philippe Goupille, Gilles Paintaud
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
infliximab
pharmacokinetics
target-mediated drug disposition
inflammatory bowel diseases
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/e2d78037197449f6a4091c5a92ae7319
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/e2d78037197449f6a4091c5a92ae7319

Ejemplares similares